News

Equa, marketed as Galvus in the EU, has been approved in Japan for the treatment of type 2 diabetes, as monotherapy or in combination with a sulfonylurea. As

OBI-1 is indicated for the treatment of patients with acquired hemophilia and hemophilia A, who have developed an inhibitory immune reaction to human forms of factor VIII. IB1001

Reportedly, ChemPoint will manage the complete order and fulfillment process for SolVin’s Ixan SGA-1 PVDC resin, from order placement to delivery to technical support. Diego Lancksweert, business manager

GAI-122 is being developed as IV administered formulation of an intracellular neuro-protectant that employs AlphaRx’s proprietary nano-emulsion formulation technology. More specifically, GAI-122 is being developed for the amelioration

The MiniFiler kit, designed to obtain DNA results from compromised or degraded samples, has utility in a wide range of investigations, including cold cases, missing person cases, exonerations

The patent entitled ‘Sustained-Release Bupropion and Bupropion/Mecamylamine Tablets’ discloses the formulation of pharmaceutical tablets containing sustained-release granules of bupropion HCl distributed in a sustained-release matrix. Horst Zerbe, president

Reportedly, the data from phase III programs conducted in MS, were included in the applications for regulatory approval submitted to the FDA and European Medicines Agency (EMEA), in

4SC-203 is a multi-target kinase inhibitor having selectivity profile against FLT3, FLT3 mutants and VEGF-Receptors in both in-vitro and in-vivo studies. FLT3 represents an attractive therapeutic target in

Dr Whaley Bishnoi and her team specialise in tunable nanoparticle sensors that look at local pH on an intercellular level. They use the Zetasizer Nano to measure the